Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 11:36 ET | Source: Spherix Global Insights

Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies

Exton, PA, May 28, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the 2026 update of Market Dynamix™: Idiopathic Inflammatory Myopathies (IIM), US, revealing a market increasingly...
May 27, 2026 10:40 ET | Source: Spherix Global Insights

Eli Lilly’s Oral GLP-1 Foundayo Trails Novo Nordisk’s Wegovy Pill in Early Obesity Launch Uptake, According to Spherix Global Insights

Exton, PA, May 27, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients...
May 21, 2026 11:25 ET | Source: Spherix Global Insights

Real-World CAR-T Delays in LBCL Drive Reliance on Bridging Therapy, According to Spherix Global Insights

Exton, PA, May 21, 2026 (GLOBE NEWSWIRE) -- Despite growing adoption of CAR-T therapy in large B-cell lymphoma (LBCL), new findings from Spherix Global Insights suggest that operational and...
May 19, 2026 10:16 ET | Source: Spherix Global Insights

Sotyktu’s Psoriatic Arthritis Launch Builds Gradually in Month Two as Rheumatologists Continue to Take Measured Approach to TYK2 Adoption, According to Spherix Global Insights

Exton, PA, May 19, 2026 (GLOBE NEWSWIRE) -- Data collected between May 4 and May 9, 2026 through Spherix Global Insights’ Launch Dynamix™ service suggest Bristol Myers Squibb’s Sotyktu...
May 13, 2026 09:15 ET | Source: Spherix Global Insights

SGLT2 Inhibitors Entrenched as Foundational CKD Therapy While GLP-1 Adoption Remains Selective, According to Spherix Global Insights

Exton, PA, May 13, 2026 (GLOBE NEWSWIRE) -- Nephrologists are initiating SGLT2 inhibitors earlier in the chronic kidney disease (CKD) treatment journey and continuing them well below labeled eGFR...
May 05, 2026 14:18 ET | Source: Spherix Global Insights

Lupus Patients Continue to Navigate Delayed Diagnosis, High Disease Burden, and Complex Treatment Journeys, According to Spherix Global Insights

Exton, PA, May 05, 2026 (GLOBE NEWSWIRE) -- New findings from Spherix Global Insights’ Patient Voice Dynamix™: Systemic Lupus Erythematosus (SLE) 2026 highlight a market still defined by high...
April 29, 2026 10:51 ET | Source: Spherix Global Insights

Spherix Advances Oncology Leadership with Novel PD-1 Findings and Inaugural Presence at American Society of Clinical Oncology (ASCO) Annual Meeting 2026

Exton, PA, April 29, 2026 (GLOBE NEWSWIRE) -- Breadth of physician-driven research underscores emerging trends in oncology as three abstracts are accepted at ASCO 2026: Operational and...
April 24, 2026 10:18 ET | Source: Spherix Global Insights

Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment

Exton, PA, April 24, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape evolves, new access channels are reshaping how patients receive care. Since the launch of Eli Lilly’s LillyDirect in...
April 17, 2026 13:20 ET | Source: Spherix Global Insights

Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity

Exton, PA, April 17, 2026 (GLOBE NEWSWIRE) -- New data from Spherix Global Insights’ Launch Dynamix™ service indicate that rebalancing agents are continuing to establish a foothold in hemophilia...
April 13, 2026 10:42 ET | Source: Spherix Global Insights

SLE Market Evolution Accelerates as AstraZeneca’s Saphnelo SC Emerges as a Likely Key Challenger to GSK’s Benlysta

Exton, PA, April 13, 2026 (GLOBE NEWSWIRE) -- The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying...